ABBV AbbVie Inc.

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

The Vanguard Group, Inc. ( IRSH)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

04-Feb-2020 / 14:17 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Ap19

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY INFORMATION

 

Name of person dealing (Note 1)

The Vanguard Group, Inc.

Company dealt in

AbbVie plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.01 common stock

Date of dealing

03 February 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

123,106,768

8.32%

39,403

0.00%

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

123,106,768

8.32%

39,403

0.00%
           

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

 

 

Ap20

 

1.  Dealings (Note 4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Sale

79,043

81.02 USD

Purchase

354,239

81.02 USD

Purchase

42,911

81.03 USD

 

 

(b)  Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Not Applicable

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

(i)  Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Not Applicable

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

Not Applicable

 

 

 

 

(e)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Not Applicable

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                           NO

 

Date of disclosure

04 February 2020

Contact name

Shawn Acker

Telephone number

001-610-669-8989

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 
Category Code: RET - AbbVie plc
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 44490
EQS News ID: 967525

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=967525&application_name=news&site_id=research_pool
EN
04/02/2020

Underlying

ABBVAbbVie Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AbbVie Inc.

ABBV ABBVIE INC.

Moody's Ratings upgrades AbbVie to A2; outlook is stable

Moody's Ratings (Moody's) upgraded the ratings of AbbVie Inc. ("AbbVie") including the long-term issuer rating to A2 from A3, senior unsecured notes to A2 from A3, and the senior unsecured commercial paper rating to Prime-1 from Prime-2. At the same time, we revised AbbVie's outlook to stable from p...

6h / 26m 6h / 26m 1 EN
ABBV ABBVIE INC.

AbbVie Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

12/08/25 December 8, 2025 1 EN
 PRESS RELEASE
Free
ABBV ABBVIE INC.

L’Agence des médicaments du Canada émet une recommandation positive po...

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies inflammatoires de l’intestin, initialement pour la maladie de Crohn et maintenant pour la colite ulcéreuse. Ces recommandations s’appuient sur l...

November 28, 2025 1 EN
 PRESS RELEASE
Free
ABBV ABBVIE INC.

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation...

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie c...

November 28, 2025 1 EN
 PRESS RELEASE
Free
ABBV ABBVIE INC.

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with ...

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch